July 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
Focused on Changing Breast Cancer Outcomes
PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.
On average, every two minutes a woman is diagnosed with breast cancer in the United States.
About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.
About PreciseDx
PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.
Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists
Better Data. Better Outcomes.
PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.
- Patients
- Providers
- Payers
- BioPharma
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Patients
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
Providers
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
Payers
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
BioPharma
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Gold Corporate Member
Jack Zeineh, PreciseDx
Gold Corporate Member
Featured News & Resources
Press Release
Publication
July 9, 2024
Journal of Medical Economics
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
Poster
June 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
Media Coverage
May 31, 2024
COTA, Baptist Health South Florida, PreciseDx collaborate on AI-based test for IBC recurrence
Media Coverage
May 31, 2024
360Dx Newsletter: Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
Media Coverage
May 31, 2024
Cota, PreciseDx, Baptist Health South Florida to Assess Invasive Breast Cancer Recurrence Test
Press Release
July 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
Publication
July 9, 2024
Journal of Medical Economics
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
Poster
June 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up